OP9-DL1 hDL-1-Expressing mOP9 Cell Line

OP9-DL1 is a bone marrow-derived stromal cell line stably expressing the Notch ligand Delta like I (DL1) ectopically.
Notch signaling controls multiple cell fate decisions. It is initiated via engagement of the Notch receptor with its ligands (Jagged or Delta-like family members). This is followed by cleavage of the intracellular domain of Notch and its subsequent translocation into the nucleus, where it binds with the transcription factor CBF-1/RBPJ and activates transcription of various downstream target genes. Upregulation of Notch ligands is a factor in chronic inflammatory diseases including pancreatitis and diabetic nephropathy. Several studies have implicated the role of Notch signaling in early T-cell lineage commitments, as it promotes development of T-cells with αα+ T-Cell Receptors (TCRs) at the expense of αα+ TCRs 3. Bone marrow progenitor cells expressing constitutively active Notch have been shown to develop into CD4 and CD8 double-positive T cells. This signaling pathway also plays an important role in the development of CD4+ or CD8+ single positive cells from CD4 and CD8 double-positive precursor thymocytes.

OP9 bone marrow stromal cells support the differentiation of hematopoietic progenitor cells (HPCs) into multiple lineages including B-cells, but not to T-cells. This is mainly because they do not express Delta-like 1 or Delta-like 4 notch ligands inherently. OP9 cells were therefore infected with a MiGR1 retroviral vector engineered to express the human Delta-like-1 gene and green fluorescent protein (GFP). The OP9-DL1 cells were then sorted for GFP expression.

Source
GMO. OP9-DL1 cells were genetically modified from stromal cells derived from mouse bone marrow.

References
1.Immunity 2002, 17(6): 749-756.
2.J Orthop Sci. 2005, 10(6): 589-594.
3.Curr Opin Immunol. 2007, 19(2): 163-168.
4.Cold Spring Harb Protoc. 2009, 2009(2): pdb.prot5156.

OP9 bone marrow stromal OP9-DL1 cells support the differentiation of embryonic or hematopoietic stem cells from fetal liver or bone marrow into T lymphocytes. Holmes et. al., has provided a detailed protocol to differentiate embryonic or hematopoietic stem cells into T lymphocytes using the OP9-DL1 system. The OP9-DL1 cell line is an important tool for the exploration of the role of Notch signaling in cellular differentiation and genesis of inflammatory disease states.

OP9-DL1 cells should be stored in liquid nitrogen. The cells can be cultured for at least 10 passages without significantly affecting cell marker expression and function.

Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact licensing@milliporesigma.com.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.